Skip to content

8 papers indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Sep 2026

Abstract B006: Actin Cytoskeleton Dynamics in Tumor Cells Orchestrate Stromal Desmoplasia and Immune Evasion in Pancreatic Cancer

Pancreatic ductal adenocarcinoma (PDAC) is defined by a dense, immunosuppressive tumor microenvironment (TME) enriched with extracellular matrix components, cancer-associated fibroblasts (CAFs), and diverse immune populations. ChIP-seq analysis of resected human PDAC identified MICAL2 as a super-enhancer–associat...

Bharti Garg, E. Mose, Briana Nyugen et al. · 0 citations
Sep 2026

Abstract B137: Targeting MICAL2 sensitizes pancreatic cancer cells to gemcitabine and enhances therapeutic response

Pancreatic ductal adenocarcinoma (PDAC) remains a highly lethal malignancy, largely due to rapid development of resistance to standard chemotherapies such as gemcitabine. MICAL2 is a redox-dependent regulator of actin dynamics that is overexpressed in PDAC, but its role in therapeutic resistance remains poorly un...

Ponmathi Panneerpandian, Kevin Christian Montecillo Gulay, M. Macdonald et al. · 0 citations
Sep 2026

Abstract A061: Spatial Whole-Transcriptome Profiling Reveals Immune-Suppressive Stromal Niches and Associated Ductal Tumor Cell-State Programs in Pancreatic Cancer

Pancreatic ductal adenocarcinoma (PDAC) is characterized by marked spatial heterogeneity and a highly variable immune microenvironment, ranging from myeloid-enriched, immune-suppressive regions to more immune-responsive niches. How tumor epithelial and stromal compartments contribute to these spatial immune states, a...

Yuan Sui, Jonathan R. Weitz, J. Bruning et al. · 0 citations
Sep 2026

Abstract B014: Leveraging dynamic epigenetic landscapes to decode tumor-associated macrophages in pancreatic ductal adenocarcinoma

Leveraging the MITF-dependent gene signature activated in macrophages, this work sought to address how MITF-associated enhancers are mechanistically influencing PDAC TAM functions as the tumor becomes more advanced and develops chemoresistance.

Debbie K. Ledezma, K. Gulay, Hervé Tiriac et al. · 0 citations
Sep 2026

Abstract B054: Combined RAS Inhibition and Immune Checkpoint Blockade Overcome NF-κB-Mediated Immune Evasion in Chemoresistant Pancreatic Cancer

Pancreatic ductal adenocarcinoma (PDAC) remains one of the most lethal malignancies. Surgery is the only potentially curative treatment, yet approximately 85% of patients present with unresectable disease. For these patients, chemotherapy remains the standard treatment, though nearly all develop resistance and diseas...

K. Gulay, A. Martsinkovskiy, A. Lowy et al. · 0 citations
Sep 2026

Abstract A054: MICAL2 promotes oncogenic Kras -induced pancreatic cancer initiation by regulating RAC1-mediated acinar to ductal metaplasia

Pancreatic ductal adenocarcinoma (PDAC) is a deadly form of pancreatic cancer with the poorest 5-year survival rate among all solid cancers. Therefore, identifying effective therapeutic strategies is crucial for treating this disease. Using a genome-wide screening approach to find novel and targetable factors in huma...

Nirakar Rajbhandari, Deepa Sheik Pran Babu, E. Mose et al. · 0 citations
Review Sep 2026

Abstract PR002: Surveillance-detected pancreatic cancers: Updated report from the PRECEDE Consortium

The Pancreatic Cancer Early Detection (PRECEDE) Consortium is a multinational prospective longitudinal cohort study of participants with elevated heritable risk for pancreatic adenocarcinoma, with an overarching goal to increase survival of PC by driving early detection.

R. Wadlow, Samuel D. Newton, Jessica N. Everett et al. · 0 citations
#protein folding Sep 2026

Abstract A065: Mutant GNAS drives cAMP/PDE/AMP–pAMPK signaling and therapeutic synergy with combined CDK4/6 and RAS inhibition in mucinous pancreatic neoplasia

Intraductal Papillary Mucinous Neoplasm (IPMN) are pre-malignant lesions of the pancreas with frequent co-mutations in KRAS and GNAS oncogenes. We recently reported pancreatic neoplasia from both primary and metastatic disease with KRAS/GNAS mutations are sensitive to single agent treatment with the FDA approved cell...

Deepa Sheik Pran Babu, Shira Yomtoubian, Ethan Tabibzadeh et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.